The global airway disease treatment market is expected to generate US$ 3,495.3 Million in revenue by 2032, up from US$ 1,996.1 Million in 2022, with a CAGR of 5.2% over the forecast period. The steady growth in the market is owing to:
| Report Attribute | Details |
|---|---|
| Airway Disease Treatment Market Value (2022) | US$ 1,996.1 Million |
| Airway Disease Treatment Market Anticipated Forecast Value (2032) | US$ 3,495.3 Million |
| Airway Disease Treatment Market Projected Growth Rate (2022 to 2032) | 5.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
During the projection period, the Asia Pacific market is expected to grow at a faster rate. The growing presence of major products in the region is expected to fuel demand for asthma medications between 2022 and 2032. Due to the existence of major players, China and Japan are projected to provide considerable potential in the market. For example, the rise of Pulmicort, a crucial asthma medicine, in the area has been driven by a favorable performance in China.
This factor, together with the availability of a huge and underserved market in the region, is expected to fuel market expansion in the Asia Pacific throughout the projection period. The rest of the international market, which includes Latin America, the Middle East, and Africa, is still in its infancy. However, it is anticipated that throughout the projection period, rising chronic respiratory illness incidence and rising product introductions, especially effective generic asthma treatments, are likely to drive demand for airway disease treatments.
Globally, growing nations are opening up significant potential in the market for the treatment of respiratory disorders due to the high incidence of respiratory illnesses, increased accessibility to high-quality healthcare services, and expansion of the pharmaceutical sector. The market for airway disease treatment has numerous growth opportunities due to the quick uptake of new technology and a surge in innovation.
During the drug development phase, pharmaceutical companies devote a significant amount of both monetary and non-monetary resources. The companies are completely in charge of the drug's manufacture and manufacturing while they have the patents for it. The original pharmaceutical producer suffers significant losses as a result of generic drug manufacturers using the formula to produce their versions of the medications, which poses a difficult situation for the expansion of the global market.
As these businesses are positioned to acquire market share throughout the forecast period through the increased sales of their product offerings, this is anticipated to have a favorable influence on the airway disease treatment market growth.
Principal Consultant
The market's competitive landscape shows a monopoly market structure with a large number of enterprises present. Due to the strength of their products in terms of asthma medications, two companies, AstraZeneca and GlaxoSmithKline dominated this industry.
The most notable products for GlaxoSmithKline were Advair and Flovent HFA/Flovent Diskus. These are the key elements that have contributed significantly to these firms' leading market positions. However, there are other well-known market participants, like Merck and Teva, which have sizable market revenue shares in the international market.
A generic asthma medication called fluticasone propionate and salmeterol inhalation powder, which is intended for the treatment of both asthma and chronic obstructive pulmonary disease, has completed phase III clinical research, according to Cipla Inc. (COPD). This potential possibility is the 100/50 mcg generic version of Advair Diskus.
Among the medications used in combination therapy for COPD are LABA-ICS, LAMA-ICS, triple therapy, and other similar drugs. Due to its superior efficacy over using a bronchodilator and a corticosteroid separately, combination therapy is becoming more popular, propelling the demand for airway disease treatment.
The airway disease treatment market growth is likely to augment owing to a rise in the number of patients who are successfully treated with combination therapy but who were not responding to bronchodilators or corticosteroid treatments. In addition, the adoption of airway disease treatment soars as the symptoms and quality of life of patients with chronic obstructive pulmonary disease can be improved more successfully with combination therapy than with monotherapy.
Combination therapy has also gained traction on account of recent regulatory approvals and a rise in the success rate of the treatment for COPD, aiding the overall market. Furthermore, the development of cutting-edge therapeutics for asthma by major market players is one of the critical factors holding sway over the airway disease treatment market trends and forecasts.
The adoption of airway disease treatment is facilitated by market characteristics such as solid and robust Research and Development efforts. One of the significant airway disease treatment market trends is the involvement of well-known pharmaceutical companies in the development of asthma medications, as asthma is a chronic disease that affects a sizable number of patients worldwide.
As part of this involvement, several promising asthma treatment candidates are currently undergoing various stages of clinical trials, influencing airway disease treatment adoption trends. For instance, in September 2019, Novartis released encouraging data from the phase III IRIDIUM study of the inhaled combination QVM149 in patients with uncontrolled asthma.
On account of the rising prevalence of respiratory diseases such as asthma, cystic fibrosis, and COPD across the world, the demand for airway disease treatment is expected to skyrocket to a considerable extent. And the same can be primarily owed to the highly susceptible elderly people to respiratory diseases (COPD, asthma, emphysema) due to reduced immunity and blood flow.
Furthermore, the airway disease treatment market's key trends & opportunities are shaped by the introduction of advanced imaging technologies such as digital radiography and computed radiography as they render high-quality digital images.
Digital imaging systems have witnessed a low adoption rate as these are more expensive than analog imaging systems, dwindling the overall airway disease treatment market size during the forecast period. Since the pandemic and asthma are closely related to respiratory illnesses, there is an increased need for various types of asthma treatment medications, in turn, spiking the demand for airway disease treatment.
Due to rising demand and adoption of airway disease treatment, the USA FDA has granted priority regulatory approvals to several asthma medications, including important generic alternatives.
A key generic asthma treatment drug from Cipla, for example, received regulatory approval from the USA FDA in April 2020. Lupin is also expected to receive regulatory approval for a generic version of the same medication, auguring well for the airway disease treatment market's future trends.
The market is also positively impacted by the surging release of products with significant capability from well-known companies as a result of such developments and trends. Further efforts are made to prevent significant shortages of asthma medications by launching an increasing number of products.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Geographically, North America is anticipated to hold a major chunk of the airway disease treatment market share accounting for 38.1% in 2022.
The dominance of North America can be attributed to the rising incidence of respiratory diseases, the popularity of portable electronics, and the rising need for equipment and services for in-home medical care.
According to the American Lung Association, COPD is the third most common cause of death in the country. Additionally, a growing need for cutting-edge and inventive products in medical facilities, diagnostic labs, and outpatient ambulatory surgery centers would drive market expansion in the region.
Europe holds second place in the market for treatments for airway disease, projected to dominate a market share of 22.5% in 2022.
The region's market is being driven by a well-established healthcare system and an increase in the prevalence of chronic obstructive pulmonary disease and Asthma is the most common issue among children.
A number of technological advancements in respiratory diagnostic testing have paved the way for the market's expansion, including the use of artificial intelligence and the Internet of things (IoT), among other things.
A US-based start-up, Altavant Sciences, is advancing therapies for managing rare respiratory diseases. The company's lead drug candidate, rodaristat ethyl, is a small molecule inhibitor of tryptophan hydroxylase (TPH).
The medication reduces serotonin levels in conditions like PAH and idiopathic pulmonary fibrosis (IPF). The start-up is also working on medicines to treat bronchiolitis obliterans syndrome. Exvastat, a British start-up, creates a drug that is modified to treat acute respiratory distress syndrome (ARDS).
Imatinib, a medication used to treat chronic myeloid leukemia, is being reformulated by the start-up. The newly developed medication makes use of its capacity to obstruct vascular leak, a cause of pulmonary edema.
Currently, the global airway disease treatment market is highly competitive owing to the involvement of many established players.
Some of the key players in the global airway disease treatment market are Holaira, Inc., VIDA Diagnostics, Boehringer Ingelheim International GmBH, AstraZeneca, Teva Pharmaceuticals, GlaxoSmithKline and Novartis.
Some of the recent developments in the airway disease treatment market are:
These medications are intended to treat chronic obstructive pulmonary disease (COPD).
For people with asthma, this drug is frequently regarded as a last resort.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.2% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
Type, Treatment, End Use, Region |
| Regions Covered |
North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Japan; The Middle East and Africa |
| Key Countries Profiled |
United States of America, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC Countries, South Africa |
| Key Companies Profiled |
Holaira, Inc.; VIDA Diagnostics; Boehringer Ingelheim International GmBH; AstraZeneca; Teva Pharmaceuticals; GlaxoSmithKline; Novartis |
| Customization | Available Upon Request |
The global airway disease treatment market is set to advance at a CAGR of 5.2% (2022 to 2032).
North America is likely to hold an airway disease treatment market share of 38.1% in 2022.
The airway disease treatment market is predicted to account for US$ 3,495.3 Million by 2032.
1. Executive Summary | Airway Disease Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2022 to 2032
5.3.1. Asthma
5.3.2. Chronic Obstructive Pulmonary Disorder
5.3.3. Bronchiectasis
5.4. Y-o-Y Growth Trend Analysis By Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Type, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2022 to 2032
6.3.1. Bronchodilators
6.3.2. Corticosteroids
6.3.3. Cytotoxic Drugs
6.3.4. Oxygen Therapy
6.3.5. Antibiotics
6.3.6. Others
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Treatment, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-user
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2022 to 2032
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. ASCs
7.3.4. Rehabilitation Centers
7.3.5. Others
7.4. Y-o-Y Growth Trend Analysis By End-user, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By End-user, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Treatment
9.2.4. By End-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Treatment
9.3.4. By End-user
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Treatment
10.2.4. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Treatment
10.3.4. By End-user
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. By Treatment
11.2.4. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Treatment
11.3.4. By End-user
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. India
12.2.1.5. Malaysia
12.2.1.6. Singapore
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia-Pacific
12.2.2. By Type
12.2.3. By Treatment
12.2.4. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Treatment
12.3.4. By End-user
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa
13.2.2. By Type
13.2.3. By Treatment
13.2.4. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Treatment
13.3.4. By End-user
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. United States of America
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Type
14.1.2.2. By Treatment
14.1.2.3. By End-user
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Type
14.2.2.2. By Treatment
14.2.2.3. By End-user
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Type
14.3.2.2. By Treatment
14.3.2.3. By End-user
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Type
14.4.2.2. By Treatment
14.4.2.3. By End-user
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Type
14.5.2.2. By Treatment
14.5.2.3. By End-user
14.6. United Kingdom.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Type
14.6.2.2. By Treatment
14.6.2.3. By End-user
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Type
14.7.2.2. By Treatment
14.7.2.3. By End-user
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Type
14.8.2.2. By Treatment
14.8.2.3. By End-user
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Type
14.9.2.2. By Treatment
14.9.2.3. By End-user
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Type
14.10.2.2. By Treatment
14.10.2.3. By End-user
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Type
14.11.2.2. By Treatment
14.11.2.3. By End-user
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Type
14.12.2.2. By Treatment
14.12.2.3. By End-user
14.13. Malaysia
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Type
14.13.2.2. By Treatment
14.13.2.3. By End-user
14.14. Singapore
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Type
14.14.2.2. By Treatment
14.14.2.3. By End-user
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Type
14.15.2.2. By Treatment
14.15.2.3. By End-user
14.16. New Zealand
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Type
14.16.2.2. By Treatment
14.16.2.3. By End-user
14.17. GCC Countries
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Type
14.17.2.2. By Treatment
14.17.2.3. By End-user
14.18. South Africa
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Type
14.18.2.2. By Treatment
14.18.2.3. By End-user
14.19. Israel
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Type
14.19.2.2. By Treatment
14.19.2.3. By End-user
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Type
15.3.3. By Treatment
15.3.4. By End-user
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Nuvaira
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. VIDA Diagnostics
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Boehringer Ingelheim International GmBH
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. AstraZeneca
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Teva Pharmaceuticals
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. GlaxoSmithKline
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Novartis
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Merck
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Roche
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Sanofi
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Airway Disease Treatment Market
